Impact of 18F-FDG PET used after initial treatment of cancer: Comparison of the national oncologic PET registry 2006 and 2009 cohorts

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 831-837

  Hillner, Bruce E ^a   Siegel, Barry A ^b   Hanna, Lucy ^c   Shields, Anthony F ^d   Duan, Fenghai ^c   Gareen, Ilana F ^c   Quinn, Bruce ^e   Coleman, R Edward ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Foley Hoag LLC   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multiple cancer types; Patient registry; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GOVERNMENT; HEALTH CARE POLICY; HUMAN; KIDNEY CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEOPLASM; PANCREAS CANCER; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STOMACH CANCER; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UTERUS CANCER;

COHORT STUDIES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; REGISTRIES; TREATMENT OUTCOME;

EID: 84860710620     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.103911     Document Type: Article

References (15)

1. Decision memo for positron emission tomography (FDG) for solid tumors (CAG-00181R). Centers for Medicare & Medicaid Services Web site. Available at: Http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo. aspx?NCAId5218&fromdb5true&bc5AAAAAAAAABAA. Published April 3, 2009. Accessed March 12, 2012.
2. Transmittal AB-01-54, Expanded coverage of positron emission tomography (PET) scans and related claims processing changes. Centers for Medicare & Medicaid Services Web site. Available at: Http://www.cms.gov/transmittals/ downloads/AB0154.pdf. Accessed March 12, 2012.
3. Lindsay MJ, Siegel BA, Tunis SR, et al. The National Oncologic PET Registry: Expanded Medicare coverage for PET under coverage with evidence development. AJR. 2007;188:1109-1113. (Pubitemid 46496951)
4. Coverage with evidence development Medicare coverage-general information. Centers for Medicare & Medicaid Services Web site. Available at: Https://www.cms.gov/CoverageGenInfo/03-CED.asp. Accessed March 20, 2012.
5. Tunis S, Whicher D. The National Oncologic PET Registry: Lessons learned for coverage with evidence development. J Am Coll Radiol. 2009;6:360-365.
6. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): Design and analysis plan. J Nucl Med. 2007;48:1901-1908. (Pubitemid 350099337)
7. Hillner BE, Siegel BA, Shields AF, et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: Findings of the National Oncologic PET Registry. Cancer. 2009;115:410-418.
8. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the National Oncologic PET Registry. J Nucl Med. 2008;49:1928-1935.
9. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-2161.
10. Hillner BE, Siegel BA, Shields AF, et al. Impact of dedicated brain PET on intended patient management in participants of the National Oncologic PET Registry. Mol Imaging Biol. 2011;13:161-165.
11. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508. (Pubitemid 351355215)
12. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50 (suppl):1S-10S.
13. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(suppl):11S-20S.
14. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009 50(suppl 1):122S-150S.
15. Aridgides P, Bogart J, Shapiro A, Gajra A. PET response-guided treatment of Hodgkin's lymphoma: A review of the evidence and active clinical trials. Adv Hematol. 2011:309237.